Acute renal insufficiency, supraventricular tachycardia, and confusion after recombinant human bone morphogenetic protein-2 implantation for lumbosacral spine fusion.

The authors report on a case of a patient who received recombinant human bone morphogenetic protein-2 (rhBMP-2) to augment spinal fusion for the first and third of 3 lumbosacral fusion surgeries. After receiving rhBMP-2 the first time, the patient became febrile and developed mild acute renal insufficiency and transient supraventricular tachycardia (SVT). The second operation was complicated only by perioperative fever. When the patient received rhBMP-2 again during the third operation, he developed fever, acute oliguric renal insufficiency, symptomatic SVT with hypoxemia, confusion, and joint pain. No clear cause of these problems was identified; however serum analysis revealed the presence of an antibody to rhBMP-2. The authors discuss potential mechanisms for the patient's putative reaction to rhBMP-2, as the findings from a literature review suggest this is the first such reaction to be reported.

[1]  Dong Liu,et al.  Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility. , 2007, Cardiovascular research.

[2]  S. Glassman,et al.  Clinical Outcomes and Fusion Success at 2 Years of Single-Level Instrumented Posterolateral Fusions With Recombinant Human Bone Morphogenetic Protein-2/Compression Resistant Matrix Versus Iliac Crest Bone Graft , 2006, Spine.

[3]  K. Bulsara,et al.  Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. , 2005, Journal of neurosurgery. Spine.

[4]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[5]  B. Egbert,et al.  Development of a Novel Nonantigenic Dermal Implant Composed of Human Placental Collagen , 2004, Plastic and reconstructive surgery.

[6]  B. Chandrasekar,et al.  BMP‐2 regulates cardiomyocyte contractility in a phosphatidylinositol 3 kinase‐dependent manner , 2003, FEBS letters.

[7]  N. Wright,et al.  Bone morphogenetic proteins and spinal fusion. , 2002, Neurosurgical focus.

[8]  C. Dickman,et al.  Anterior Lumbar Interbody Fusion Using rhBMP-2 With Tapered Interbody Cages , 2002, Journal of spinal disorders & techniques.

[9]  J. Lane,et al.  Safety Profile for the Clinical Use of Bone Morphogenetic Proteins in the Spine , 2002, Spine.

[10]  H. Sandhu,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 in Spinal Fusion Applications , 2002, Spine.

[11]  Safdar N. Khan,et al.  Bone morphogenetic proteins: relevance in spine surgery. , 2002, The Orthopedic clinics of North America.

[12]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[13]  S. Boden,et al.  The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report , 2000, Spine.

[14]  G. Charriere,et al.  Bovine collagen induced systemic symptoms: antibody formation against bovine and human collagen. , 1996, The Journal of rheumatology.

[15]  F. Delustro,et al.  Clinical use of injectable bovine collagen: a decade of experience. , 1992, Clinical materials.

[16]  J. Dasch,et al.  Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives. , 1990, Clinical orthopaedics and related research.

[17]  J. McPherson,et al.  The human immune response to reconstituted bovine collagen. , 1986, Journal of immunology.

[18]  N. Swanson,et al.  Intradermal implantation of bovine collagen. Humoral immune responses associated with clinical reactions. , 1984, Archives of dermatology.

[19]  L Cooperman,et al.  The immunogenicity of injectable collagen. I. A 1-year prospective study. , 1984, Journal of the American Academy of Dermatology.

[20]  L. Cooperman,et al.  The immunogenicity of injectable collagen. II. A retrospective review of seventy-two tested and treated patients. , 1984, Journal of the American Academy of Dermatology.